Recent advances in understanding schizophrenia

F1000Prime Reports

Volumn 6, Issue , 2014, Pages

  Haller, Chiara S ^a,b,c,d   Padmanabhan, Jaya L ^c,d   Lizano, Paulo ^c,d   Torous, John ^c,d   Keshavan, Matcheri ^b,c,d  

^a HARVARD UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c MASSACHUSETTS MENTAL HEALTH CENTER   (United States)

^d BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NEUROLEPTIC AGENT; NEUROTRANSMITTER;

ARTICLE; BEHAVIORAL RESEARCH; COGNITIVE DEFECT; DSM-5; EARLY INTERVENTION; ENVIRONMENTAL FACTOR; FAMILY THERAPY; GROUP THERAPY; HUMAN; HYPOTHESIS; LIFE EXPECTANCY; LIFESPAN; NATIONAL HEALTH ORGANIZATION; NEGATIVE SYNDROME; NERVE CELL PLASTICITY; NEUROPATHOLOGY; PATHOPHYSIOLOGY; PSYCHOSIS; PSYCHOSOCIAL CARE; SCHIZOPHRENIA; SOCIAL ADAPTATION; TREATMENT OUTCOME;

EID: 84904861720     PISSN: None     EISSN: 20517599     Source Type: Journal    
DOI: 10.12703/P6-57     Document Type: Article

References (123)

1. Kraepelin E: Manic depressive insanity and paranoia. The Journal of Nervous and Mental Disease 1921, 53:350.
2. Heckers S: Is schizoaffective disorder a useful diagnosis? Curr Psychiatry Rep 2009, 11:332-7.
3. Feighner JP, Robins E, Guze SB, Woodruff RA, Winokur G, Munoz R: Diagnostic criteria for use in psychiatric research. Arch Gen Psychiatry 1972, 26:57-63.
4. Schneider K: Clinical Psychopathology. New York, NY: Grune & Stratton. City Inc; 1959.
5. Rimol LM, Hartberg CB, Nesvåg R, Fennema-Notestine C, Hagler DJ, Pung CJ, Jennings RG, Haukvik UK, Lange E, Nakstad PH, Melle I, Andreassen OA, Dale AM, Agartz I: Cortical thickness and subcortical volumes in schizophrenia and bipolar disorder. Biol. Psychiatry 2010, 68:41-50.
6. Purcell SM, Wray NR, Stone JL, Visscher PM, O'Donovan MC, Sullivan PF, Sklar P: Common polygenic variation contributes to risk of schizophrenia and bipolar disorder. Nature 2009, 460:748-52.
7. Ivleva EI, Morris DW, Moates AF, Suppes T, Thaker GK, Tamminga CA: Genetics and intermediate phenotypes of the schizophrenia-bipolar disorder boundary. Neurosci Biobehav Rev 2010, 34:897-921.
8. Keshavan MS, Clementz BA, Pearlson GD, Sweeney JA, Tamminga CA: Reimagining psychoses: an agnostic approach to diagnosis. Schizophr Res 2013, 146:10-6.
9. Insel T, Cuthbert B, Garvey M, Heinssen R, Pine DS, Quinn K, Sanislow C, Wang P: Research domain criteria (RDoC): toward a new classification framework for research on mental disorders. Am J Psychiatry 2010, 167:748-51.
10. Kahn RS, Keefe Richard S E: Schizophrenia is a cognitive illness: time for a change in focus. JAMA Psychiatry 2013, 70:1107-12.
11. Keshavan MS, Kulkarni S, Bhojraj T, Francis A, Diwadkar V, Montrose DM, Seidman LJ, Sweeney J: Premorbid cognitive deficits in young relatives of schizophrenia patients. Front Hum Neurosci 2010, 3:62.
12. Fusar-Poli P, Smieskova R, Kempton MJ, Ho BC, Andreasen NC, Borgwardt S: Progressive brain changes in schizophrenia related to antipsychotic treatment? A meta-analysis of longitudinal MRI studies. Neurosci Biobehav Rev 2013, 37:1680-91.
13. Cornblatt BA, Carrión RE, Addington J, Seidman L, Walker EF, Cannon TD, Cadenhead KS, McGlashan TH, Perkins DO, Tsuang MT, Woods SW, Heinssen R, Lencz T: Risk factors for psychosis: impaired social and role functioning. Schizophr Bull 2012, 38:1247-57.
14. Cannon TD, Cadenhead K, Cornblatt B, Woods SW, Addington J, Walker E, Seidman LJ, Perkins D, Tsuang M, McGlashan T, Heinssen R: Prediction of psychosis in youth at high clinical risk: a multisite longitudinal study in North America. Arch Gen Psychiatry 2008, 65:28-37.
15. Ruhrmann S, Schultze-Lutter F, Salokangas Raimo K R, Heinimaa M, Linszen D, Dingemans P, Birchwood M, Patterson P, Juckel G, Heinz A, Morrison A, Lewis S, von Reventlow Heinrich Graf, Klosterkötter J: Prediction of psychosis in adolescents and young adults at high risk: results from the prospective European prediction of psychosis study. Arch Gen Psychiatry 2010, 67:241-51.
16. Brent BK, Thermenos HW, Keshavan MS, Seidman LJ: Gray matter alterations in schizophrenia high-risk youth and early-onset schizophrenia: a review of structural MRI findings. Child Adolesc Psychiatr Clin N Am 2013, 22:689-714.
17. van Tricht Mirjam J, Ruhrmann S, Arns M, Müller R, Bodatsch M, Velthorst E, Koelman Johannes H T M, Lo Bour J, Zurek K, Schultze-Lutter F, Klosterkötter J, Linszen DH, de Haan L, Brockhaus-Dumke A, Nieman DH: Can quantitative EEG measures predict clinical outcome in subjects at Clinical High Risk for psychosis? A prospective multicenter study. Schizophr Res 2014, 153:42-7.
18. Woodberry KA, Seidman LJ, Giuliano AJ, Verdi MB, Cook WL, McFarlane WR: Neuropsychological profiles in individuals at clinical high risk for psychosis: relationship to psychosis and intelligence. Schizophr Res 2010, 123:188-98.
19. Walker EF, Trotman HD, Pearce BD, Addington J, Cadenhead KS, Cornblatt BA, Heinssen R, Mathalon DH, Perkins DO, Seidman LJ, Tsuang MT, Cannon TD, McGlashan TH, Woods SW: Cortisol levels and risk for psychosis: initial findings from the North American prodrome longitudinal study. Biol Psychiatry 2013, 74:410-7.
20. Addington J, Cadenhead KS, Cannon TD, Cornblatt B, McGlashan TH, Perkins DO, Seidman LJ, Tsuang M, Walker EF, Woods SW, Heinssen R: North American Prodrome Longitudinal Study: a collaborative multisite approach to prodromal schizophrenia research. Schizophr Bull 2007, 33:665-72. (Pubitemid 47343713)
21. Sullivan PF, Kendler KS, Neale MC: Schizophrenia as a complex trait: evidence from a meta-analysis of twin studies. Arch Gen Psychiatry 2003, 60:1187-92. (Pubitemid 37494071)
22. Williams HJ, Norton N, Dwyer S, Moskvina V, Nikolov I, Carroll L, Georgieva L, Williams NM, Morris DW, Quinn EM, Giegling I, Ikeda M, Wood J, Lencz T, Hultman C, Lichtenstein P, Thiselton D, Maher BS, Malhotra AK, Riley B, Kendler KS, Gill M, Sullivan P, Sklar P, Purcell S, Nimgaonkar VL, Kirov G, Holmans P, Corvin A, Rujescu D, et al.: Fine mapping of ZNF804A and genome-wide significant evidence for its involvement in schizophrenia and bipolar disorder. Mol Psychiatry 2011, 16:429-41.
23. Stefansson H, Ophoff RA, Steinberg S, Andreassen OA, Cichon S, Rujescu D, Werge T, Pietiläinen Olli P H, Mors O, Mortensen PB, Sigurdsson E, Gustafsson O, Nyegaard M, Tuulio-Henriksson A, Ingason A, Hansen T, Suvisaari J, Lonnqvist J, Paunio T, Børglum AD, Hartmann A, Fink-Jensen A, Nordentoft M, Hougaard D, Norgaard-Pedersen B, Böttcher Y, Olesen J, Breuer R, Möller H, Giegling I, et al.: Common variants conferring risk of schizophrenia. Nature 2009, 460:744-7.
24. Doherty JL, O'Donovan MC, Owen MJ: Recent genomic advances in schizophrenia. Clin Genet 2012, 81:103-9.
25. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet 2013, 381:1371-9.
26. Di Forti M, Iyegbe C, Sallis H, Kolliakou A, Falcone MA, Paparelli A, Sirianni M, La Cascia C, Stilo SA, Marques TR, Handley R, Mondelli V, Dazzan P, Pariante C, David AS, Morgan C, Powell J, Murray RM: Confirmation that the AKT1 (rs2494732) genotype influences the risk of psychosis in cannabis users. Biol Psychiatry 2012, 72:811-6.
27. Alemany S, Goldberg X, van Winkel R, Gastó C, Peralta V, Fañanás L: Childhood adversity and psychosis: examining whether the association is due to genetic confounding using a monozygotic twin differences approach. Eur Psychiatry 2013, 28:207-12.
28. Haukvik UK, Saetre P, McNeil T, Bjerkan PS, Andreassen OA, Werge T, Jönsson EG, Agartz I: An exploratory model for G x E interaction on hippocampal volume in schizophrenia; obstetric complications and hypoxia-related genes. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34:1259-65.
29. Aas M, Djurovic S, Athanasiu L, Steen NE, Agartz I, Lorentzen S, Sundet K, Andreassen OA, Melle I: Serotonin transporter gene polymorphism, childhood trauma, and cognition in patients with psychotic disorders. Schizophr Bull 2012, 38:15-22.
30. Duncan LE, Keller MC: A critical review of the first 10 years of candidate gene-by-environment interaction research in psychiatry. Am J Psychiatry 2011, 168:1041-9.
31. Balu DT, Li Y, Puhl MD, Benneyworth MA, Basu AC, Takagi S, Bolshakov VY, Coyle JT: Multiple risk pathways for schizophrenia converge in serine racemase knockout mice, a mouse model of NMDA receptor hypofunction. Proc Natl Acad Sci USA 2013, 110:E2400-9.
32. Timms AE, Dorschner MO, Wechsler J, Choi KY, Kirkwood R, Girirajan S, Baker C, Eichler EE, Korvatska O, Roche KW, Horwitz MS, Tsuang DW: Support for the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia from exome sequencing in multiplex families. JAMA Psychiatry 2013, 70:582-90.
33. Moghaddam B, Javitt D: From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment. Neuropsychopharmacology 2012, 37:4-15.
34. Feinberg I: Schizophrenia: caused by a fault in programmed synaptic elimination during adolescence? J Psychiatr Res 1982, 17:319-34.
35. Keshavan MS, Anderson S, Pettegrew JW: Is schizophrenia due to excessive synaptic pruning in the prefrontal cortex? The Feinberg hypothesis revisited. J Psychiatr Res 1994, 28:239-65. (Pubitemid 24195531)
36. Lewis DA, Curley AA, Glausier JR, Volk DW: Cortical parvalbumin interneurons and cognitive dysfunction in schizophrenia. Trends Neurosci 2012, 35:57-67.
37. Sohal VS, Zhang F, Yizhar O, Deisseroth K: Parvalbumin neurons and gamma rhythms enhance cortical circuit performance. Nature 2009, 459:698-702.
38. Matthews PR, Eastwood SL, Harrison PJ: Reduced myelin basic protein and actin-related gene expression in visual cortex in schizophrenia. PLoS ONE 2012, 7:e38211.
39. Catts VS, Fung SJ, Long LE, Joshi D, Vercammen A, Allen KM, Fillman SG, Rothmond DA, Sinclair D, Tiwari Y, Tsai S, Weickert TW, Shannon Weickert C: Rethinking schizophrenia in the context of normal neurodevelopment. Front Cell Neurosci 2013, 7:60.
40. Harrison PJ: The neuropathology of schizophrenia. A critical review of the data and their interpretation. Brain 1999, 122 (Pt 4):593-624.
41. Howes O, Bose S, Turkheimer F, Valli I, Egerton A, Stahl D, Valmaggia L, Allen P, Murray R, McGuire P: Progressive increase in striatal dopamine synthesis capacity as patients develop psychosis: a PET study. Mol Psychiatry 2011, 16:885-6.
42. Tandon N, Bolo NR, Sanghavi K, Mathew IT, Francis AN, Stanley JA, Keshavan MS: Brain metabolite alterations in young adults at familial high risk for schizophrenia using proton magnetic resonance spectroscopy. Schizophr Res 2013, 148:59-66.
43. Song X, Fan X, Song X, Zhang J, Zhang W, Li X, Gao J, Harrington A, Ziedonis D, Lv L: Elevated levels of adiponectin and other cytokines in drug naïve, first episode schizophrenia patients with normal weight. Schizophr Res 2013, 150:269-73.
44. Bergink V, Gibney SM, Drexhage HA: Autoimmunity, inflammation, and psychosis: a search for peripheral markers. Biol Psychiatry 2014, 75:324-31.
45. Smyth AM, Lawrie SM: The Neuroimmunology of Schizophrenia. Clin Psychopharmacol Neurosci 2013, 11:107-17.
46. Flatow J, Buckley P, Miller BJ: Meta-analysis of oxidative stress in schizophrenia. Biol Psychiatry 2013, 74:400-9.
47. Finke C, Kopp UA, Prüss H, Dalmau J, Wandinger K, Ploner CJ: Cognitive deficits following anti-NMDA receptor encephalitis. J Neurol Neurosurg Psychiatr 2012, 83:195-8.
48. Zandi MS, Irani SR, Lang B, Waters P, Jones PB, McKenna P, Coles AJ, Vincent A, Lennox BR: Disease-relevant autoantibodies in first episode schizophrenia. J Neurol 2011, 258:686-8.
49. Benros ME, Mortensen PB, Eaton WW: Autoimmune diseases and infections as risk factors for schizophrenia. Ann N Y Acad Sci 2012, 1262:56-66.
50. Shepherd AM, Laurens KR, Matheson SL, Carr VJ, Green MJ: Systematic meta-review and quality assessment of the structural brain alterations in schizophrenia. Neurosci Biobehav Rev 2012, 36:1342-56.
51. Honea R, Crow TJ, Passingham D, Mackay CE: Regional deficits in brain volume in schizophrenia: a meta-analysis of voxel-based morphometry studies. Am J Psychiatry 2005, 162:2233-45. (Pubitemid 41740200)
52. Minzenberg MJ, Laird AR, Thelen S, Carter CS, Glahn DC: Metaanalysis of 41 functional neuroimaging studies of executive function in schizophrenia. Arch Gen Psychiatry 2009, 66:811-22.
53. Gur RE, Loughead J, Kohler CG, Elliott MA, Lesko K, Ruparel K, Wolf DH, Bilker WB, Gur RC: Limbic activation associated with misidentification of fearful faces and flat affect in schizophrenia. Arch Gen Psychiatry 2007, 64:1356-66. (Pubitemid 350223553)
54. Yao L, Lui S, Liao Y, Du M, Hu N, Thomas JA, Gong Q: White matter deficits in first episode schizophrenia: an activation likelihood estimation meta-analysis. Prog Neuropsychopharmacol Biol Psychiatry 2013, 45:100-6.
55. Catani M, Mesulam M: The arcuate fasciculus and the disconnection theme in language and aphasia: history and current state. Cortex 2008, 44:953-61.
56. Zhang R, Wei Q, Kang Z, Zalesky A, Li M, Xu Y, Li L, Wang J, Zheng L, Wang B, Zhao J, Zhang J, Huang R: Disrupted brain anatomical connectivity in medication-naïve patients with first-episode schizophrenia. Brain Struct Funct 2014.
57. DELAY J, LAINE B, BUISSON JF: Note concernant l'action de l'isonicotinyl-hydrazide utilisé dans le traitement des états dépressifs. Ann Med Psychol (Paris) 1952, 110:689-92.
58. Miyamoto S, Wolfgang W: 5 Pharmacologic Treatment of. Comprehensive Care of Schizophrenia: A Textbook of Clinical Management 2012:4.
59. Johnstone EC, Crow TJ, Frith CD, Carney MW, Price JS: Mechanism of the antipsychotic effect in the treatment of acute schizophrenia. Lancet 1978, 1:848-51. (Pubitemid 8321793)
60. Kapur S, Remington G: Atypical antipsychotics: new directions and new challenges in the treatment of schizophrenia. Annu Rev Med 2001, 52:503-17. (Pubitemid 32195338)
61. Leucht S, Cipriani A, Spineli L, Mavridis D, Orey D, Richter F, Samara M, Barbui C, Engel RR, Geddes JR, Kissling W, Stapf MP, Lässig B, Salanti G, Davis JM: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 2013, 382:951-62.
62. Davidson M, Galderisi S, Weiser M, Werbeloff N, Fleischhacker WW, Keefe RS, Boter H, Keet Ireneus P M, Prelipceanu D, Rybakowski JK, Libiger J, Hummer M, Dollfus S, López-Ibor JJ, Hranov LG, Gaebel W, Peuskens J, Lindefors N, Riecher-Rössler A, Kahn RS: Cognitive effects of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: a randomized, open-label clinical trial (EUFEST). Am J Psychiatry 2009, 166:675-82.
63. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe Richard S E, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-23. (Pubitemid 41345943)
64. Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, Reimherr F, McGee MF, Keefe Richard S E, McEvoy JP, Hsiao JK, Lieberman JA: Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am J Psychiatry 2007, 164:428-36. (Pubitemid 46513156)
65. Breier A, Schreiber JL, Dyer J, Pickar D: National Institute of Mental Health longitudinal study of chronic schizophrenia. Prognosis and predictors of outcome. Arch Gen Psychiatry 1991, 48:239-46.
66. Tandon R, Ribeiro SC, DeQuardo JR, Goldman RS, Goodson J, Greden JF: Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication. Biol Psychiatry 1993, 34:495-7. (Pubitemid 23337734)
67. Buchanan RW, Panagides J, Zhao J, Phiri P, den Hollander W, Ha X, Kouassi A, Alphs L, Schooler N, Szegedi A, Cazorla P: Asenapine versus olanzapine in people with persistent negative symptoms of schizophrenia. J Clin Psychopharmacol 2012, 32:36-45.
68. Mazure CM, Nelson JC, Jatlow PI, Bowers MB: Drug-responsive symptoms during early neuroleptic treatment. Psychiatry Res 1992, 41:147-54.
69. Leucht S, Arbter D, Engel RR, Kissling W, Davis JM: How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trials. Mol Psychiatry 2009, 14:429-47.
70. Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch Gen Psychiatry 2003, 60:553-64. (Pubitemid 36682312)
71. Leucht S, Corves C, Arbter D, Engel RR, Li C, Davis JM: Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet 2009, 373:31-41.
72. Glick ID, Correll CU, Altamura AC, Marder SR, Csernansky JG, Weiden PJ, Leucht S, Davis JM: Mid-term and long-term efficacy and effectiveness of antipsychotic medications for schizophrenia: a data-driven, personalized clinical approach. J Clin Psychiatry 2011, 72:1616-27.
73. Kishimoto T, Agarwal V, Kishi T, Leucht S, Kane JM, Correll CU: Relapse prevention in schizophrenia: a systematic review and meta-analysis of second-generation antipsychotics versus first-generation antipsychotics. Mol Psychiatry 2013, 18:53-66.
74. Wahlbeck K, Cheine M, Essali A, Adams C: Evidence of clozapine's effectiveness in schizophrenia: a systematic review and metaanalysis of randomized trials. Am J Psychiatry 1999, 156:990-9. (Pubitemid 29302789)
75. Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B: Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and metaanalysis of randomized trials. Am J Psychiatry 2001, 158:518-26. (Pubitemid 32289814)
76. Lewis SW, Barnes Thomas R E, Davies L, Murray RM, Dunn G, Hayhurst KP, Markwick A, Lloyd H, Jones PB: Randomized controlled trial of effect of prescription of clozapine versus other second-generation antipsychotic drugs in resistant schizophrenia. Schizophr Bull 2006, 32:715-23. (Pubitemid 44412859)
77. McEvoy JP, Lieberman JA, Stroup TS, Davis SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe Richard S E, Davis CE, Severe J, Hsiao JK: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006, 163:600-10. (Pubitemid 44464569)
78. Souza JS, Kayo M, Tassell I, Martins CB, Elkis H: Efficacy of olanzapine in comparison with clozapine for treatment-resistant schizophrenia: evidence from a systematic review and meta-analyses. CNS Spectr 2013, 18:82-9.
79. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, Keefe Richard S E, Davis SM, Davis CE, Lebowitz BD, Severe J, Hsiao JK: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005, 353:1209-23. (Pubitemid 41345943)
80. Johnsen E, Jørgensen HA: Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008, 8:31.
81. Leucht S, Komossa K, Rummel-Kluge C, Corves C, Hunger H, Schmid F, Asenjo Lobos C, Schwarz S, Davis JM: A meta-analysis of head-to-head comparisons of second-generation antipsychotics in the treatment of schizophrenia. Am J Psychiatry 2009, 166:152-63.
82. Kreyenbuhl J, Buchanan R, Kelly D, Noel J, Boggs D, Fischer B, Himelhoch S, Fang B, Peterson E, Aquino P: The 2009 schizophrenia patient outcomes research team (PORT) psychopharmacological treatment recommendations. International Clinical Psychopharmacology 2011, 26:e54-e55.
83. Patil ST, Zhang L, Martenyi F, Lowe SL, Jackson KA, Andreev BV, Avedisova AS, Bardenstein LM, Gurovich IY, Morozova MA, Mosolov SN, Neznanov NG, Reznik AM, Smulevich AB, Tochilov VA, Johnson BG, Monn JA, Schoepp DD: Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat Med 2007, 13:1102-7. (Pubitemid 47517511)
84. Keefe Richard S E, Buchanan RW, Marder SR, Schooler NR, Dugar A, Zivkov M, Stewart M: Clinical trials of potential cognitive-enhancing drugs in schizophrenia: what have we learned so far? Schizophr Bull 2013, 39:417-35.
85. Kishimoto T, Nitta M, Borenstein M, Kane JM, Correll CU: Long-acting injectable versus oral antipsychotics in schizophrenia: a systematic review and meta-analysis of mirror-image studies. J Clin Psychiatry 2013, 74:957-65.
86. Remington G, Seeman P, Feingold A, Mann S, Shammi C, Kapur S: "Extended" antipsychotic dosing in the maintenance treatment of schizophrenia: a double-blind, placebo-controlled trial. J Clin Psychiatry 2011, 72:1042-8.
87. Wunderink L, Nieboer RM, Wiersma D, Sytema S, Nienhuis FJ: Recovery in remitted first-episode psychosis at 7 years of follow-up of an early dose reduction/discontinuation or maintenance treatment strategy: long-term follow-up of a 2-year randomized clinical trial. JAMA Psychiatry 2013, 70:913-20.
88. Hanson DR, Gottesman II: Theories of schizophrenia: a genetic-inflammatory-vascular synthesis. BMC Med Genet 2005, 6:7.
89. Monji A, Kato TA, Mizoguchi Y, Horikawa H, Seki Y, Kasai M, Yamauchi Y, Yamada S, Kanba S: Neuroinflammation in schizophrenia especially focused on the role of microglia. Prog Neuropsychopharmacol Biol Psychiatry 2013, 42:115-21.
90. Potvin S, Stip E, Sepehry AA, Gendron A, Bah R, Kouassi E: Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol Psychiatry 2008, 63:801-8. (Pubitemid 351410515)
91. Miller BJ, Buckley P, Seabolt W, Mellor A, Kirkpatrick B: Metaanalysis of cytokine alterations in schizophrenia: clinical status and antipsychotic effects. Biol Psychiatry 2011, 70:663-71.
92. Brown AS, Derkits EJ: Prenatal infection and schizophrenia: a review of epidemiologic and translational studies. Am J Psychiatry 2010, 167:261-80.
93. Sørensen HJ, Nielsen PR, Pedersen CB, Benros ME, Nordentoft M, Mortensen PB: Population impact of familial and environmental risk factors for schizophrenia: A nationwide study. Schizophr Res 2014, 153:214-9.
94. Sommer IE, Neggers Sebastian F W: Repetitive transcranial magnetic stimulation as a treatment for auditory hallucinations. Neuropsychopharmacology 2014, 39:239-40.
95. Sommer IE, van Westrhenen R, Begemann Marieke J H, de Witte Lot D, Leucht S, Kahn RS: Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull 2014, 40:181-91.
96. Arranz MJ, Rivera M, Munro JC: Pharmacogenetics of response to antipsychotics in patients with schizophrenia. CNS Drugs 2011, 25:933-69.
97. Zhang J, Malhotra AK: Pharmacogenetics of antipsychotics: recent progress and methodological issues. Expert Opin Drug Metab Toxicol 2013, 9:183-91.
98. Müller DJ, Chowdhury NI, Zai CC: The pharmacogenetics of antipsychotic-induced adverse events. Curr Opin Psychiatry 2013, 26:144-50.
99. Ravyn D, Ravyn V, Lowney R, Nasrallah HA: CYP450 pharmacogenetic treatment strategies for antipsychotics: a review of the evidence. Schizophr Res 2013, 149:1-14.
100. Dixon LB, Dickerson F, Bellack AS, Bennett M, Dickinson D, Goldberg RW, Lehman A, Tenhula WN, Calmes C, Pasillas RM, Peer J, Kreyenbuhl J: The 2009 schizophrenia PORT psychosocial treatment recommendations and summary statements. Schizophr Bull 2010, 36:48-70.
101. Thase ME: Comparative effectiveness of psychodynamic psychotherapy and cognitive-behavioral therapy: it's about time, and what's next? Am J Psychiatry 2013, 170:953-6.
102. Goldin PR, Ziv M, Jazaieri H, Werner K, Kraemer H, Heimberg RG, Gross JJ: Cognitive reappraisal self-efficacy mediates the effects of individual cognitive-behavioral therapy for social anxiety disorder. J Consult Clin Psychol 2012, 80:1034-40.
103. Kern RS, Glynn SM, Horan WP, Marder SR: Psychosocial treatments to promote functional recovery in schizophrenia. Schizophr Bull 2009, 35:347-61.
104. Wykes T, Steel C, Everitt B, Tarrier N: Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor. Schizophr Bull 2008, 34:523-37.
105. Grant PM, Reisweber J, Luther L, Brinen AP, Beck AT: Successfully Breaking a 20-Year Cycle of Hospitalizations With Recovery-Oriented Cognitive Therapy for Schizophrenia. Psychol Serv 2013.
106. Elis O, Caponigro JM, Kring AM: Psychosocial treatments for negative symptoms in schizophrenia: current practices and future directions. Clin Psychol Rev 2013, 33:914-28.
107. Cormac I, Jones C, Campbell C, Silveira dMNJ: Cognitive behaviour therapy for schizophrenia. The Cochrane Library 2004.
108. Horan WP, Kern RS, Tripp C, Hellemann G, Wynn JK, Bell M, Marder SR, Green MF: Efficacy and specificity of social cognitive skills training for outpatients with psychotic disorders. J Psychiatr Res 2011, 45:1113-22.
109. Dickinson D, Bellack AS, Gold JM: Social/communication skills, cognition, and vocational functioning in schizophrenia. Schizophr Bull 2007, 33:1213-20. (Pubitemid 47347910)
110. Rus-Calafell M, Gutiérrez-Maldonado J, Ribas-Sabaté J: A virtual reality-integrated program for improving social skills in patients with schizophrenia: a pilot study. J Behav Ther Exp Psychiatry 2014, 45:81-9.
111. Malik N: Family Systems Theory. Encyclopedia of Behavioral Medicine 2013, 774-75.
112. Burns T, Catty J, Dash M, Roberts C, Lockwood A, Marshall M: Use of intensive case management to reduce time in hospital in people with severe mental illness: systematic review and meta-regression. BMJ 2007, 335:336.
113. Remington G, Foussias G, Agid O: Progress in defining optimal treatment outcome in schizophrenia. CNS Drugs 2010, 24:9-20.
114. Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Flesher S, Reiss D, Carter M, Ulrich R: Personal therapy: a disorder-relevant psychotherapy for schizophrenia. Schizophr Bull 1995, 21:379-93.
115. Hogarty GE, Kornblith SJ, Greenwald D, DiBarry AL, Cooley S, Ulrich RF, Carter M, Flesher S: Three-year trials of personal therapy among schizophrenic patients living with or independent of family I: description of study and effects on relapse rates. FOCUS: The Journal of Lifelong Learning in Psychiatry 2004, 2:146-157.
116. Kay T: Neuropsychological treatment of mild traumatic brain injury. The Journal of Head Trauma Rehabilitation 1993, 8:74-85.
117. Elgamal S, McKinnon MC, Ramakrishnan K, Joffe RT, MacQueen G: Successful computer-assisted cognitive remediation therapy in patients with unipolar depression: a proof of principle study. Psychol Med 2007, 37:1229-38. (Pubitemid 47244853)
118. Lask B: Cognitive Remediation Therapy. Eating Disorders in Childhood and Adolescence 2013, 301.
119. Hodge Marie Antoinette Redoblado, Siciliano D, Withey P, Moss B, Moore G, Judd G, Shores EA, Harris A: A randomized controlled trial of cognitive remediation in schizophrenia. Schizophr Bull 2010, 36:419-27.
120. Eack SM, Mesholam-Gately RI, Greenwald DP, Hogarty SS, Keshavan MS: Negative symptom improvement during cognitive rehabilitation: results from a 2-year trial of Cognitive Enhancement Therapy. Psychiatry Res 2013, 209:21-6.
121. Bond GR: Principles of the Individual Placement and Support model: Empirical support. Psychiatr Rehabil J 1998, 22:11.
122. Bond GR, Drake RE, Becker DR: An update on randomized controlled trials of evidence-based supported employment. Psychiatr Rehabil J 2008, 31:280-90. (Pubitemid 351579863)
123. Killackey E, Jackson HJ, McGorry PD: Vocational intervention in first-episode psychosis: individual placement and support v. treatment as usual. The British journal of psychiatry 2008, 193:114-120.